In a laboratory at the University of Helsinki, two molecular compounds did what no drug candidate has managed before: they triggered myelin regrowth in cells mimicking multiple sclerosis damage. The breakthrough, reported in Tapani Koppinen's doctoral thesis defended earlier this month, offers the first real glimmer of hope for a disease that has defeated every remyelination candidate ever tested.
Multiple sclerosis strikes about three million people worldwide, with particularly high rates across Northern Europe and Canada. The disease works by turning the immune system against myelin, the insulating sheath that wraps nerve fibers and allows electrical signals to travel efficiently through the brain and spinal cord. Today's MS medications suppress that immune attack—a genuine advance for many patients—but they cannot repair myelin that has already been destroyed. For people with progressive MS, where damage accumulates relentlessly over years, this limitation is devastating.
Remyelination, the natural process by which myelin regrows around damaged nerve fibers, holds the key to true recovery. In healthy brains, specialized cells called oligodendrocytes continuously repair such damage. But in MS, especially in advanced stages, this repair capacity collapses. The damaged tissue itself becomes hostile to healing, developing scar tissue and internal conditions that actively block oligodendrocytes from doing their work. Researchers have spent years searching for ways to unlock remyelination—to restart the brain's own repair system—only to watch every attempt fail in preclinical development.
Koppinen, working under Associate Professor Merja Voutilainen in the University of Helsinki's research group, took two entirely different approaches. The first molecule targets the unfolded protein response, a stress mechanism inside brain cells that becomes chronically overactive in MS-damaged tissue. This constant state of cellular stress prevents repair-promoting cells from functioning. By blocking it, Koppinen's molecule increased remyelination and accelerated the process in tissue showing MS-like damage. Results from this work appeared in Molecular Therapy in October 2025.
The second molecule addresses the physical barrier itself: the scar tissue that encases damaged areas and mechanically prevents nerve repair. By altering the composition of that scar, the molecule creates an environment where remyelination can proceed. This work was published in Neuropharmacology in November 2025.
What makes these findings particularly striking is not just that both molecules worked, but that they worked through completely different mechanisms and achieved strikingly similar results. Both also cleared a critical hurdle: they crossed the blood-brain barrier in laboratory animals, solving one of the most persistent technical challenges in designing brain-targeted drugs.
This is not yet a cure. The research remains in animal and cell models, nowhere near the complexity of the human brain. No remyelination candidate has entered clinical trials, let alone reached patients. "The goal is to enable the molecules we have developed to reach clinical trials, which could one day produce the first drugs that enhance remyelination in MS," Koppinen says.
But for the millions of people living with progressive MS—those for whom current treatments offer only a slowing of decline, not genuine recovery—these molecules represent something unprecedented. They are the furthest along any remyelination candidate has ever come. The gap between treatments that slow disease and treatments that repair it is finally beginning to close.